Identification

Name
Alprazolam
Accession Number
DB00404  (APRD00280, DB05925)
Type
Small Molecule
Groups
Approved, Illicit, Investigational
Description

A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of panic disorders, with or without agoraphobia, and in generalized anxiety disorders. (From AMA Drug Evaluations Annual, 1994, p238)

Structure
Thumb
Synonyms
  • 8-Chloro-1-methyl-6-phenyl-4H-S-triazolo(4,3-a)(1,4)benzodiazepine
  • Alprazolam
External IDs
TUS-1 / U 31,889 / U-31,889 / U-31889
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlprazolamTablet.25 mg/1Oralbryant ranch prepack1981-10-16Not applicableUs
AlprazolamTablet.25 mg/1OralGreenstone, Llc1981-10-16Not applicableUs
AlprazolamTablet0.25 mgOralSanis Health Inc2010-04-30Not applicableCanada
AlprazolamTablet0.5 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
AlprazolamTablet.5 mg/1OralContract Pharmacy Services Pa1981-10-16Not applicableUs
AlprazolamTablet0.25 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
AlprazolamTablet2 mg/1OralGreenstone, Llc1981-10-16Not applicableUs
AlprazolamTablet1 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2011-11-302017-01-18Us
AlprazolamTablet1 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
AlprazolamTablet2 mg/1Oralbryant ranch prepack1981-10-16Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlprazolamTablet.5 mg/1OralMylan Institutional1998-10-23Not applicableUs
AlprazolamTablet1 mg/1OralSandoz1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralPreferreed Pharmaceuticals Inc.2016-03-01Not applicableUs
AlprazolamTablet, extended release.5 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2007-05-242016-11-29Us
AlprazolamTablet.5 mg/1OralApotheca, Inc.2000-01-18Not applicableUs
AlprazolamTablet.5 mg/1OralRed Pharm Drug, Inc.2015-10-01Not applicableUs
AlprazolamTablet, extended release2 mg/1OralRebel Distributors2009-12-03Not applicableUs
AlprazolamTablet1 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralCardinal Health2009-12-31Not applicableUs
AlprazolamTablet2 mg/1OralPd Rx Pharmaceuticals, Inc.1998-03-25Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlprazolamTablet.25 mg/1OralDirectrx2017-11-01Not applicableUs
AlprazolamTablet1 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
AlprazolamTablet.25 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
AlprazolamTablet2 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
AlprazolamTablet.5 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
International/Other Brands
Alplax / Alprazolan / Alpronax / Alprox / Alviz / Cassadan / Esparon / Ralozam / Restyl / Solanax / Tafil / Trankimazin / Tranquinal / Xanax / Xanor
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GabazolamineAlprazolam + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
Gabazolamine-0.5Alprazolam + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
Sentrazolam AMAlprazolam + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
Categories
UNII
YU55MQ3IZY
CAS number
28981-97-7
Weight
Average: 308.765
Monoisotopic: 308.082874143
Chemical Formula
C17H13ClN4
InChI Key
VREFGVBLTWBCJP-UHFFFAOYSA-N
InChI
InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3
IUPAC Name
12-chloro-3-methyl-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene
SMILES
CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12

Pharmacology

Indication

For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia.

Structured Indications
Pharmacodynamics

Alprazolam, a benzodiazepine, is used to treat panic disorder and anxiety disorder. Unlike chlordiazepoxide, clorazepate, and prazepam, alprazolam has a shorter half-life and metabolites with minimal activity. Like other triazolo benzodiazepines such as triazolam, alprazolam may have significant drug interactions involving the hepatic cytochrome P-450 3A4 isoenzyme. Clinically, all benzodiazepines cause a dose-related central nervous system depressant activity varying from mild impairment of task performance to hypnosis. Unlike other benzodiazepines, alprazolam may also have some antidepressant activity, although clinical evidence of this is lacking.

Mechanism of action

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

TargetActionsOrganism
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption

Readily absorbed from the gastrointestinal tract. Bioavailability is 80-90%.

Volume of distribution
Not Available
Protein binding

80% (mainly to albumin)

Metabolism

Hepatic. Hydroxylated in the liver to α-hydroxyalprazolam, which is also active. This and other metabolites are later excreted in urine as glucuronides.

Route of elimination

Alprazolam and its metabolites are excreted primarily in the urine.

Half life

6.3-26.9 hours

Clearance
  • 2.13 +/- 0.54 mL/min/kg [CYP3A inducers]
  • 0.90 +/- 0.21 mL/min/kg [without CYP3A inducers]
Toxicity

Oral, mouse: LD50=1020 mg/kg. Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Alprazolam can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Alprazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Alprazolam can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Alprazolam can be decreased when combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Alprazolam is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alfentanil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Allopregnanolone.Investigational
AlogliptinThe serum concentration of Alprazolam can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Alprazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alphaprodine.Illicit
Ambroxol acefyllinateThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Ambroxol acefyllinate.Experimental, Investigational
AminophyllineThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Alprazolam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Alprazolam can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Alprazolam can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Alprazolam can be increased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Alprazolam can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Alprazolam can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Alprazolam can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Alprazolam can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Alprazolam can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Alprazolam can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Azaperone.Investigational, Vet Approved
AzelastineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Alprazolam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Barbital.Illicit
BatimastatThe serum concentration of Alprazolam can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Alprazolam can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Alprazolam can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Alprazolam is combined with Benzyl alcohol.Approved
BivalirudinThe serum concentration of Alprazolam can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Alprazolam can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Alprazolam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Alprazolam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Alprazolam.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Bupivacaine.Approved, Investigational
BuprenorphineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alprazolam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Alprazolam.Approved
CamostatThe serum concentration of Alprazolam can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Alprazolam can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Alprazolam can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Alprazolam is combined with Canertinib.Investigational
CapecitabineThe metabolism of Alprazolam can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Alprazolam can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Alprazolam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carbinoxamine.Approved
CarbomycinThe serum concentration of Alprazolam can be increased when it is combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Alprazolam can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Alprazolam.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Alprazolam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Alprazolam can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Alprazolam can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Alprazolam can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Alprazolam can be increased when it is combined with Cilazapril.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Alprazolam is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Alprazolam can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Alprazolam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Alprazolam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clozapine.Approved
CobicistatThe metabolism of Alprazolam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Alprazolam.Approved, Illicit
ConivaptanThe serum concentration of Alprazolam can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Alprazolam can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Alprazolam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Alprazolam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of Alprazolam can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Alprazolam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dapoxetine.Investigational
DarexabanThe serum concentration of Alprazolam can be increased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Alprazolam can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Alprazolam can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Alprazolam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Alprazolam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Alprazolam can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Alprazolam can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Alprazolam can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydrocodeine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Alprazolam.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Alprazolam.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Alprazolam.Experimental
DihydroergotamineThe metabolism of Alprazolam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Alprazolam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Alprazolam can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Doxepin.Approved
DoxycyclineThe metabolism of Alprazolam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Alprazolam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit
DronedaroneThe metabolism of Alprazolam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Dyphylline.Approved
EcabetThe serum concentration of Alprazolam can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Alprazolam can be increased when it is combined with Edoxaban.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Alprazolam is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Alprazolam can be increased when it is combined with Elafin.Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Eltanolone.Investigational
EnalaprilThe serum concentration of Alprazolam can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Alprazolam can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Alprazolam can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Alprazolam can be decreased when it is combined with Enzalutamide.Approved
Epigallocatechin GallateThe serum concentration of Alprazolam can be increased when it is combined with Epigallocatechin Gallate.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Alprazolam.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Alprazolam.Approved
ErythromycinThe serum concentration of Alprazolam can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Alprazolam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alprazolam.Approved
EthanolAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Alprazolam can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ezogabine.Approved
FaldaprevirThe serum concentration of Alprazolam can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flibanserin.Approved
FloxuridineThe metabolism of Alprazolam can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Alprazolam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Alprazolam can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Alprazolam can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Alprazolam can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Alprazolam can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Alprazolam can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Alprazolam can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Alprazolam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Alprazolam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gabapentin Enacarbil.Approved
GabexateThe serum concentration of Alprazolam can be increased when it is combined with Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GeldanamycinThe serum concentration of Alprazolam can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Alprazolam can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Glutethimide.Approved, Illicit
GM6001The serum concentration of Alprazolam can be increased when it is combined with GM6001.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alprazolam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved
IdelalisibThe serum concentration of Alprazolam can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Alprazolam can be increased when it is combined with Idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Iloperidone.Approved
ImatinibThe metabolism of Alprazolam can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Alprazolam can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Alprazolam can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Alprazolam is combined with Indiplon.Investigational
IrbesartanThe metabolism of Alprazolam can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Alprazolam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe serum concentration of Alprazolam can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsradipineThe metabolism of Alprazolam can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Alprazolam can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Alprazolam can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Alprazolam can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Alprazolam can be increased when it is combined with Josamycin.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Alprazolam can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Alprazolam can be increased when it is combined with Kitasamycin.Experimental
LamotrigineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lamotrigine.Approved, Investigational
LeflunomideThe metabolism of Alprazolam can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinThe serum concentration of Alprazolam can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Alprazolam can be increased when it is combined with Letaxaban.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Alprazolam can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Alprazolam can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Alprazolam.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lithium.Approved
LobeglitazoneThe metabolism of Alprazolam can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Alprazolam can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alprazolam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lormetazepam.Approved
LosartanThe metabolism of Alprazolam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Alprazolam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Alprazolam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Alprazolam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Alprazolam.Illicit, Investigational, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Vet Approved
ManidipineThe metabolism of Alprazolam can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Medetomidine.Vet Approved
MelagatranThe serum concentration of Alprazolam can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Alprazolam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alprazolam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Alprazolam.Experimental
MethadoneAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methohexital.Approved
MethotrimeprazineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Alprazolam.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Alprazolam.Approved
MetyrosineAlprazolam may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Alprazolam.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Alprazolam can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Alprazolam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Alprazolam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Investigational
MirtazapineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Alprazolam can be decreased when it is combined with Mitotane.Approved
MoexiprilThe serum concentration of Alprazolam can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Alprazolam.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Alprazolam can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Investigational
NafamostatThe serum concentration of Alprazolam can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nalbuphine.Approved
NefazodoneThe metabolism of Alprazolam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Alprazolam can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Alprazolam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Alprazolam can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Alprazolam can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Alprazolam.Approved, Investigational
NilotinibThe metabolism of Alprazolam can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nitrazepam.Approved
NitroaspirinThe serum concentration of Alprazolam can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alprazolam.Approved, Investigational
OlaparibThe metabolism of Alprazolam can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Alprazolam can be increased when it is combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Alprazolam can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Alprazolam can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe metabolism of Alprazolam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Alprazolam is combined with Opium.Approved, Illicit
OrphenadrineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Alprazolam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Alprazolam can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Alprazolam can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Alprazolam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paliperidone.Approved
ParaldehydeAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParitaprevirThe serum concentration of Alprazolam can be increased when it is combined with Paritaprevir.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Alprazolam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved
PerazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perazine.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Alprazolam.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Alprazolam can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Alprazolam is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Alprazolam can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Alprazolam.Approved, Vet Approved
PhosphoramidonThe serum concentration of Alprazolam can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Alprazolam.Approved
PizotifenThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Alprazolam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleAlprazolam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Alprazolam.Approved
PrazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alprazolam.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prilocaine.Approved
PrimidoneThe metabolism of Alprazolam can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Alprazolam can be increased when it is combined with Prinomastat.Investigational
ProcaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Alprazolam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Alprazolam is combined with PSD502.Investigational
PyrimethamineThe metabolism of Alprazolam can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Alprazolam can be increased when it is combined with Quinapril.Approved, Investigational
QuinineThe metabolism of Alprazolam can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quinisocaine.Experimental
RacecadotrilThe serum concentration of Alprazolam can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Alprazolam can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Alprazolam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remifentanil.Approved
RemikirenThe serum concentration of Alprazolam can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Alprazolam.Approved, Investigational
RibociclibThe serum concentration of Alprazolam can be increased when it is combined with Ribociclib.Approved
RifabutinThe metabolism of Alprazolam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Alprazolam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Alprazolam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Alprazolam can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Alprazolam can be increased when it is combined with Rivaroxaban.Approved
RomifidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Romifidine.Vet Approved
RopiniroleAlprazolam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Alprazolam.Approved
RotigotineAlprazolam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Alprazolam.Approved
S-3304The serum concentration of Alprazolam can be increased when it is combined with S-3304.Investigational
SaquinavirThe serum concentration of Alprazolam can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Alprazolam can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Alprazolam can be increased when combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Alprazolam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Alprazolam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Alprazolam can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Alprazolam.Approved
SitagliptinThe serum concentration of Alprazolam can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Alprazolam can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved
SolithromycinThe serum concentration of Alprazolam can be increased when it is combined with Solithromycin.Investigational
SorafenibThe metabolism of Alprazolam can be decreased when combined with Sorafenib.Approved, Investigational
SpiraprilThe serum concentration of Alprazolam can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Alprazolam can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Alprazolam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Alprazolam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Alprazolam can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Alprazolam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sultopride.Experimental
SuvorexantAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Alprazolam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe serum concentration of Alprazolam can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Alprazolam can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Alprazolam.Approved
TemocaprilThe serum concentration of Alprazolam can be increased when it is combined with Temocapril.Experimental, Investigational
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Alprazolam.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrodotoxin.Investigational
ThalidomideAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thioridazine.Approved, Withdrawn
ThiorphanThe serum concentration of Alprazolam can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Alprazolam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Alprazolam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tilidine.Experimental
TipranavirThe serum concentration of Alprazolam can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Alprazolam can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Alprazolam can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Topiramate.Approved
TopiroxostatThe metabolism of Alprazolam can be decreased when combined with Topiroxostat.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Alprazolam.Approved, Investigational
TrandolaprilThe serum concentration of Alprazolam can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe metabolism of Alprazolam can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triprolidine.Approved
TylosinThe serum concentration of Alprazolam can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Alprazolam can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Alprazolam.Approved, Experimental
UlinastatinThe serum concentration of Alprazolam can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Alprazolam is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Alprazolam can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Alprazolam can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Veralipride.Experimental
VerapamilThe metabolism of Alprazolam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Vigabatrin.Approved
VildagliptinThe serum concentration of Alprazolam can be increased when it is combined with Vildagliptin.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Alprazolam is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Alprazolam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Alprazolam is combined with Xenon.Experimental
XimelagatranThe serum concentration of Alprazolam can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Alprazolam can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Alprazolam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Alprazolam can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Alprazolam can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zolazepam.Vet Approved
ZolpidemAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid taking with grapefruit juice.
  • Take with food.

References

Synthesis Reference

Hester, J.B., Jr.; US. Patent 3,681,343; August 1,1972; assigned to The Upjohn Company. Hester, J.B., Jr.; US.Patent 3,781,289; December 25,1973;assigned to The Upjohn Company. Hester, J.B., Jr.; U S . Patent 3,709898; January 9,1973; assigned to The Upjohn Company.

General References
  1. Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA: Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry. 1990 May;51(5):206-9. [PubMed:2335496]
  2. Wolf B, Griffiths RR: Physical dependence on benzodiazepines: differences within the class. Drug Alcohol Depend. 1991 Dec 31;29(2):153-6. [PubMed:1686752]
  3. Haque W, Watson DJ, Bryant SG: Death following suspected alprazolam withdrawal seizures: a case report. Tex Med. 1990 Jan;86(1):44-7. [PubMed:2300914]
  4. Hori A: Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci. 1998 Feb;52(1):13-9. [PubMed:9682928]
  5. Garcia-Algar O, Lopez-Vilchez MA, Martin I, Mur A, Pellegrini M, Pacifici R, Rossi S, Pichini S: Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin Toxicol (Phila). 2007;45(3):295-8. [PubMed:17453885]
External Links
Human Metabolome Database
HMDB14548
KEGG Drug
D00225
KEGG Compound
C06817
PubChem Compound
2118
PubChem Substance
46507078
ChemSpider
2034
BindingDB
50001728
ChEBI
2611
ChEMBL
CHEMBL661
Therapeutic Targets Database
DAP000239
PharmGKB
PA448333
HET
08H
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Alprazolam
ATC Codes
N05BA12 — Alprazolam
AHFS Codes
  • 28:24.08 — Benzodiazepines
PDB Entries
3u5j
FDA label
Download (63.6 KB)
MSDS
Download (47.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
0Unknown StatusBasic SciencePsychotropic Drugs Effects1
1CompletedNot AvailableAlzheimer's Disease (AD) / Huntington's Disease (HD)1
1CompletedNot AvailableHealthy Volunteers10
1CompletedNot AvailablePharmacokinetics1
1CompletedBasic ScienceAnxiety Disorders1
1CompletedBasic ScienceHealthy Volunteers4
1CompletedDiagnosticDepressive Disorder and Anxiety Disorders / Healthy Volunteers1
1CompletedOtherAnxiety Disorders3
1CompletedOtherMigraines1
1CompletedTreatmentAbuse Liability of Staccato Alprazolam1
1CompletedTreatmentFeeling Anxious2
1CompletedTreatmentSocial Anxiety Disorder (SAD) / Social Phobia1
1Not Yet RecruitingPreventionPost-Operative Delirium1
1RecruitingBasic SciencePrescription Drug Abuse (Not Dependent) / Recreational Drug Use1
1TerminatedTreatmentHealthy Volunteers1
1WithdrawnBasic ScienceHealthy Volunteers2
2CompletedTreatmentAnxiety Disorders / Panic Disorders1
2CompletedTreatmentDental Anxiety1
2CompletedTreatmentGeneralized Anxiety Disorder (GAD)1
2, 3CompletedPreventionDiagnostic Esophagogastroduodenoscopy1
2, 3CompletedTreatmentStress Disorders, Post Traumatic1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedDiagnosticAnxiety Disorders1
4CompletedTreatmentFeeling Anxious2
4CompletedTreatmentGeneralized Anxiety Disorder (GAD) / Panic Disorders1
4CompletedTreatmentInferior Alveolar Nerve Block Failure1
4CompletedTreatmentPanic Disorders2
4Not Yet RecruitingTreatmentAnxiety Disease / Gynecologic Diseases1
4Not Yet RecruitingTreatmentHealthy Adults / Nootropic Potential of Hypericum and Alprazolam / Subclinical Anxious Adults1
4RecruitingOtherPsychomotor Impairment1
4TerminatedTreatmentPanic Disorders3
4Unknown StatusTreatmentGeneralized Anxiety Disorder (GAD)1
4WithdrawnTreatmentAnxiety Disorders1
Not AvailableCompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedBasic ScienceAOD Effects and Consequences1
Not AvailableRecruitingDiagnosticNeuroendocrine Tumors1

Pharmacoeconomics

Manufacturers
  • Roxane laboratories inc
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Apotex inc
  • Barr laboratories inc
  • Corepharma llc
  • Impax laboratories inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • Watson laboratories inc florida
  • Zydus pharmaceuticals usa inc
  • Pharmacia and upjohn
  • Par pharmaceutical inc
  • Schwarz pharma inc
  • Alphapharm party ltd
  • Dava international inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Sun pharma global inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Solution, concentrateOral1 mg/mL
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral0.50 mg
TabletOral1 mg/1
TabletOral2 mg/1
Tablet, extended releaseOral.5 mg/1
Tablet, extended releaseOral1 mg/1
Tablet, extended releaseOral2 mg/1
Tablet, extended releaseOral3 mg/1
Kit
TabletOral2 mg
Tablet, orally disintegratingOral.25 mg/1
Tablet, orally disintegratingOral.5 mg/1
Tablet, orally disintegratingOral1 mg/1
Tablet, orally disintegratingOral2 mg/1
TabletOral.25 mg
TabletOral.5 mg
TabletOral0.25 mg
TabletOral0.5 mg
TabletOral1 mg
Prices
Unit descriptionCostUnit
ALPRAZolam Intensol 1 mg/ml Concentrate 30ml Bottle67.03USD bottle
Niravam 2 mg Dispersible Tablet8.53USD dispersible tablet
Xanax xr 3 mg tablet7.25USD tablet
Xanax XR 3 mg 24 Hour tablet7.1USD tablet
Niravam 2 mg tablet6.86USD tablet
Niravam 1 mg Dispersible Tablet5.42USD dispersible tablet
Xanax xr 2 mg tablet4.84USD tablet
Xanax XR 2 mg 24 Hour tablet4.73USD tablet
Niravam 0.5 mg Dispersible Tablet4.2USD dispersible tablet
Niravam 1 mg tablet4.04USD tablet
Xanax 2 mg tablet3.82USD tablet
ALPRAZolam 3 mg 24 Hour tablet3.67USD tablet
Xanax XR 1 mg 24 Hour tablet3.64USD tablet
Xanax xr 1 mg tablet3.64USD tablet
Niravam 0.25 mg Dispersible Tablet3.45USD dispersible tablet
Niravam 0.5 mg tablet3.02USD tablet
Xanax XR 0.5 mg 24 Hour tablet3.01USD tablet
Xanax xr 0.5 mg tablet2.93USD tablet
ALPRAZolam 2 mg 24 Hour tablet2.53USD tablet
Niravam 0.25 mg tablet2.43USD tablet
ALPRAZolam 1 mg 24 Hour tablet2.33USD tablet
Xanax 1 mg tablet2.29USD tablet
Alprazolam 1 mg/ml oral conc2.23USD ml
Xanax 0.5 mg tablet1.3USD tablet
Alprazolam 2 mg tablet1.22USD tablet
Xanax 0.25 mg tablet1.09USD tablet
ALPRAZolam 0.5 mg 24 Hour tablet1.07USD tablet
Alprazolam 1 mg tablet0.78USD tablet
Alprazolam 0.5 mg tablet0.67USD tablet
Alprazolam 0.25 mg tablet0.55USD tablet
Apo-Alpraz 0.5 mg Tablet0.1USD tablet
Mylan-Alprazolam 0.5 mg Tablet0.1USD tablet
Novo-Alprazol 0.5 mg Tablet0.1USD tablet
Apo-Alpraz 0.25 mg Tablet0.08USD tablet
Mylan-Alprazolam 0.25 mg Tablet0.08USD tablet
Novo-Alprazol 0.25 mg Tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6221392No1998-04-092018-04-09Us
US6024981No1998-04-092018-04-09Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)228-229.5 °CHester, J.B., Jr.; US. Patent3,681,343; August 1,1972; assigned to The Upjohn Company. Hester, J.B., Jr.; US.Patent3,781,289; December 25,1973;assigned to The Upjohn Company. Hester, J.B., Jr.; U S . Patent 3,709898; January 9,1973; assigned t o The Upjohn Company.
water solubility40 mg/L at pH 7; 12 mg/mL at pH 1.2Not Available
logP2.12BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0324 mg/mLALOGPS
logP2.23ALOGPS
logP2.37ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)18.3ChemAxon
pKa (Strongest Basic)5.08ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.07 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity98.88 m3·mol-1ChemAxon
Polarizability32.22 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9794
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5099
P-glycoprotein inhibitor INon-inhibitor0.7301
P-glycoprotein inhibitor IIInhibitor0.8354
Renal organic cation transporterInhibitor0.7688
CYP450 2C9 substrateNon-substrate0.7907
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateSubstrate0.7353
CYP450 1A2 substrateInhibitor0.8758
CYP450 2C9 inhibitorInhibitor0.8076
CYP450 2D6 inhibitorNon-inhibitor0.8137
CYP450 2C19 inhibitorInhibitor0.6519
CYP450 3A4 inhibitorNon-inhibitor0.6308
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8913
Ames testNon AMES toxic0.8957
CarcinogenicityNon-carcinogens0.6779
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3717 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.973
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0kdi-4792000000-9f1cdda14e36000955d3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a59-0079000000-e4c35fb4df41aa5cc62e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0bt9-0169000000-0e6779728f3bdec2acf1
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0910000000-9efa6a8a3dea17fc1ce7

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2,4-triazolo[4,3-a][1,4]benzodiazepines. These are aromatic compounds containing a 1,4-benzodiazepine fused to and sharing a nitrogen atom with a 1,2,4-triazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,2,4-triazolo[4,3-a][1,4]benzodiazepines
Alternative Parents
Benzene and substituted derivatives / Aryl chlorides / Triazoles / Heteroaromatic compounds / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
1,2,4-triazolo[4,3-a][1,4]benzodiazepine / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Azole / 1,2,4-triazole / Heteroaromatic compound / Ketimine / Propargyl-type 1,3-dipolar organic compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organochlorine compound, triazolobenzodiazepine (CHEBI:2611)

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
  2. Verster JC, Volkerts ER: Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev. 2004 Spring;10(1):45-76. [PubMed:14978513]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34